Larimar Therapeutics, Inc. (LRMR)
NASDAQ: LRMR · IEX Real-Time Price · USD
3.40
-0.13 (-3.68%)
Nov 28, 2023, 4:00 PM EST - Market closed
Company Description
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform.
Its lead product candidate is CTI-1601, which is in Phase 2 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease.
The company is headquartered in Bala Cynwyd, Pennsylvania.
Larimar Therapeutics, Inc.
| Country | United States |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 26 |
| CEO | Dr. Carole S. Ben-Maimon M.D. |
Contact Details
Address: Three Bala Plaza East. Suite 506 Bala Cynwyd, Pennsylvania 19004 United States | |
| Phone | 844-511-9056 |
| Website | larimartx.com |
Stock Details
| Ticker Symbol | LRMR |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001374690 |
| CUSIP Number | 517125100 |
| ISIN Number | US5171251003 |
| Employer ID | 20-3857670 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Carole S. Ben-Maimon M.D. | Chief Executive Officer, President and Director |
| Michael Celano CPA | Secretary and Chief Financial Officer |
| John Berman | Vice President of Finance and Operations |
| Jennifer Spokes Johansson | Vice President of Regulatory Affairs and Counsel |
| Dr. Nancy M. Ruiz | Chief Medical Officer |
| Francis Michael Conway | Vice President and Controller |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 14, 2023 | 10-Q | Quarterly Report |
| Nov 14, 2023 | 8-K | Current Report |
| Oct 3, 2023 | 8-K | Current Report |
| Aug 18, 2023 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Aug 14, 2023 | 8-K | Current Report |
| Aug 10, 2023 | 10-Q | Quarterly Report |
| Aug 10, 2023 | 8-K | Current Report |
| Jul 25, 2023 | 8-K | Current Report |
| Jul 24, 2023 | 144 | Filing |
| Jul 17, 2023 | 8-K | Current Report |